In addition, the occurrence of irAEs predicted a favorable OS in patients with cancer receiving PD-1 inhibitors (HR, 0.51, 95% CI, 0.40–0.64, p < 0.001), but not CTLA-4 inhibitors (HR, 0.89, 95% CI, 0.49–1.61, p = 0.706). This evidence concerns the gene PDCD1 and cancer.